Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. PRTA.NASDAQ

Prothena Corporation plc (PRTA NASDAQ) stock market data APIs

$25.09 0.66(2.7%) as of July 26, 2024
Price chart is built with Anychart

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc Financial Data Overview

24.43
25.09
-
25.4066
24.14
18.69-70.09
1 314 M
53 772 K
89 251 K
-1.34
0.205
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PRTA',
Type: 'Common Stock',
Name: 'Prothena Corporation plc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG003PDKJF7',
ISIN: NULL,
CUSIP: NULL,
CIK: '1559053',
EmployerIdNumber: '98-1111119',
FiscalYearEnd: 'December',
IPODate: '2012-12-21',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Prothena Corporation plc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 89 251 K
  • EBITDA -215 296 992
  • Earnings Per Share -3.21
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Prothena Corporation plc Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -1.2

Get Prothena Corporation plc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Prothena Corporation plc latest news via APIs

Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recur...

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate ...
Do you have any questions?
support@eodhistoricaldata.com